Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19

    NEXT STORY
    Ziopharm Oncology Announces Election of James Huang as Chairman of the Board of Directors
    PREV STORY
    Teladoc Health Issues Inaugural Corporate Social Responsibility Report
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Axsome Therapeutics To Report First Quarter 2019 Financial Results On May 9, 2019

    author_avatar
    NASDAQ Market News

    OSE Immunotherapeutics Signs a License Option Agreement with Inserm to Develop a New Cancer Immunotherapy Targeting Myeloid Cells

    NANTES, France, Sept. 28, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE) today ...

    author_avatar
    NASDAQ Market News

    ABLYNX TO PRESENT AT THE 35th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

    Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will present at the 35th Annual J.P. Morgan ...

    author_avatar
    NASDAQ Market News